<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:40:31Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3101045" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3101045</identifier><datestamp>2011-06-02</datestamp><setSpec>yonseimj</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="brief-report">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Yonsei Med J</journal-id>
      <journal-id journal-id-type="publisher-id">YMJ</journal-id>
      <journal-title-group>
        <journal-title>Yonsei Medical Journal</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0513-5796</issn>
      <issn pub-type="epub">1976-2437</issn>
      <publisher>
        <publisher-name>Yonsei University College of Medicine</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3101045</article-id>
      <article-id pub-id-type="pmcid">PMC3101045</article-id>
      <article-id pub-id-type="pmc-uid">3101045</article-id>
      <article-id pub-id-type="pmid">21488199</article-id>
      <article-id pub-id-type="pmid">21488199</article-id>
      <article-id pub-id-type="doi">10.3349/ymj.2011.52.3.530</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Brief Communication</subject>
          <subj-group>
            <subject>Hematology</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>ADAMTS13</italic> Gene Mutations in Children with Hemolytic Uremic Syndrome</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Choi</surname>
            <given-names>Hyoung Soo</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cheong</surname>
            <given-names>Hae Il</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Nam Keun</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Oh</surname>
            <given-names>Doyeun</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Park</surname>
            <given-names>Hye Won</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Department of Pediatrics, Seoul National University Bundang Hospital, Seongnam, Korea.</aff>
      <aff id="A2"><label>2</label>Health Promotion Center, Seoul National University Bundang Hospital, Seongnam, Korea.</aff>
      <aff id="A3"><label>3</label>Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea.</aff>
      <aff id="A4"><label>4</label>Institute for Clinical Research, School of Medicine, CHA University, Seongnam, Korea.</aff>
      <aff id="A5"><label>5</label>Department of Internal Medicine, School of Medicine, CHA University, Seongnam, Korea.</aff>
      <author-notes>
        <corresp>
Co-corresponding authors: Dr. Doyeun Oh, Department of Internal Medicine, School of Medicine, CHA University, 351 Yatap-dong, Bundang-gu, Seongnam 463-712, Korea. Tel: 82-31-780-5217, Fax: 82-31-780-5208, <email>doh@cha.ac.kr</email> and Dr. Hye Won Park, Department of Pediatrics, Seoul National University Bundang Hospital, 166 Gumi-ro, Bundang-gu, Seongnam 463-707, Korea. Tel: 82-31-787-7289, Fax: 82-31-787-4054, <email>parkhyewon@dreamwiz.com</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>01</day>
        <month>5</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>06</day>
        <month>4</month>
        <year>2011</year>
      </pub-date>
      <volume>52</volume>
      <issue>3</issue>
      <fpage>530</fpage>
      <lpage>534</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>6</month>
          <year>2009</year>
        </date>
        <date date-type="rev-recd">
          <day>18</day>
          <month>11</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>26</day>
          <month>11</month>
          <year>2009</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© Copyright: Yonsei University College of Medicine 2011</copyright-statement>
        <copyright-year>2011</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0">http://creativecommons.org/licenses/by-nc/3.0</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We investigated <italic>ADAMTS13</italic> activity as well as the <italic>ADAMTS13</italic> gene mutation in children with hemolytic uremic syndrome (HUS). Eighteen patients, including 6 diarrhea-negative (D-HUS) and 12 diarrhea-associated HUS (D+HUS) patients, were evaluated. The extent of von Willebrand factor (VWF) degradation was assayed by multimer analysis, and all exons of the <italic>ADAMTS13</italic> gene were PCR-amplified using Taq DNA polymerase. The median and range for plasma activity of <italic>ADAMTS13</italic> in 6 D-HUS and 12 D+HUS patients were 71.8% (22.8-94.1%) and 84.9% (37.9-119.9%), respectively, which were not statistically significantly different from the control group (86.4%, 34.2-112.3%) (<italic>p</italic>&gt;0.05). Five <italic>ADAMTS13</italic> gene mutations, including 2 novel mutations [1584+2T&gt;A, 3941C&gt;T (S1314L)] and 3 polymorphisms (Q448E, P475S, S903L), were found in 2 D-HUS and one D+HUS patients, which were not associated with deficiency of <italic>ADAMTS13</italic> activity. Whether these mutations without reduced <italic>ADAMTS13</italic> activity are innocent bystanders or predisposing factors in HUS remains unanswered. </p>
      </abstract>
      <kwd-group>
        <kwd>
          <italic>ADAMTS13</italic>
        </kwd>
        <kwd>mutation</kwd>
        <kwd>hemolytic uremic syndrome</kwd>
        <kwd>children</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <p>Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are classified as thrombotic microangiopathy (TMA), which is characterized by occlusive microvascular thrombosis and by following thrombocytopenia, microangiopathic hemolytic anemia, and organ ischemia.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref> Acute renal failure is prominent in HUS while neurological impairment and variable degrees of renal abnormalities are found in TTP.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref> The clinical distinction between HUS and TTP is sometimes unclear because neurologic symptoms can be found in HUS and significant renal insufficiency can develop in TTP.<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref></p>
    <p>Deficiency in the von Willebrand factor (VWF)-cleaving protease, also known as <italic>ADAMTS13</italic> (a disintegrin and metalloprotease, with thrombospondin 1-like domains motif 13), is causatively related in 70-80% of TTP,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref> either by compound heterozygous or homozygous mutations in the <italic>ADAMTS13</italic> gene in congenital TTP<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref> or circulating inhibitory antibodies in the acquired form.<xref ref-type="bibr" rid="B4">4</xref></p>
    <p>However, the focus of research in HUS has been on the mechanisms of injury to the renal endothelium rather than the regulation of VWF.<xref ref-type="bibr" rid="B2">2</xref> In diarrhea-associated HUS (D+HUS), the bacterial agent Shigatoxin from Escherichia coli and Shigella dysenteriae induces the thrombotic state via direct toxic effects, resulting more in renal injury and clinical HUS.<xref ref-type="bibr" rid="B7">7</xref> In diarrhea-negative (D-HUS) or atypical HUS, more than 50% of patients have genetic abnormalities in complement regulatory genes, including complement factor H (CFH), factor I (CFI), membrane cofactor protein (MCP), and factor B (CFB) and C3.<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref> Acquired cases of D-HUS associated with CFH dysfunction due to anti-CFH autoantibodies have also been identified.<xref ref-type="bibr" rid="B8">8</xref></p>
    <p>Considering the overlapping clinical manifestation of HUS and TTP, we hypothesized that <italic>ADAMTS13</italic> would be an important factor in HUS, and therefore, investigated <italic>ADAMTS13</italic> activity as well as <italic>ADAMTS13</italic> gene mutation in children with HUS.</p>
    <p>The samples of 18 patients with HUS were sent to CHA Bundang Medical Center to test for <italic>ADAMTS13</italic> activity and <italic>ADAMTS13</italic> gene mutation from April 2004 to August 2005. The diagnosis was based on the presence or absence of diarrhea, renal dysfunction, microangiopathic hemolytic anemia and thrombocytopenia. Eighteen normal controls were recruited from those who visited the Department of Pediatrics of CHA Bundang Medical Center in the same period. In cases of decreased <italic>ADAMTS13</italic> activity (less than 44%), the presence of autoantibody in the patient's serum and the <italic>ADAMTS13</italic> activity of the parents were tested. The plasma samples were collected from patients and controls with the informed consent, according to the guidelines of the Declaration of Helsinki. The study protocol was approved by the institutional review board of the CHA Bundang Medical Center.</p>
    <p>The assay of <italic>ADAMTS13</italic> activity was performed as described previously by Furlan, et al.<xref ref-type="bibr" rid="B3">3</xref> Briefly, diluted citrated plasma was activated by barium chloride. This activated plasma was added to protease-free VWF (Green Cross, Yongin, Korea). The reaction was stopped by addition of EDTA. The extent of VWF degradation was assayed by multimer analysis using SDS-electrophoresis in 1.4% agarose gels. Following electrophoresis, the proteins were eletrotransferred to nitrocellulose, and VWF was visualized with horseradish peroxidase-conjugated goat anti-rabbit IgG against human VWF (A0082, Dako, Glostrup, Denmark). The activity was calibrated as previously described<xref ref-type="bibr" rid="B10">10</xref> with 1 : 20 to 1 : 960 dilution of normal human plasma pool.</p>
    <p>Inhibition of the <italic>ADAMTS13</italic> was assayed by measuring the remaining protease activity in the mixture of patient's plasma and normal pooled plasma at different dilution. Detection of inhibitory activity was carried out by using a screening test, by 1 : 1 mixing pools of normal plasma and patient plasma with reduced <italic>ADAMTS13</italic> activity (less than 44%) and by incubating for 30 minutes at 37â. Thereafter, the mixture was diluted to 1 : 10 in Tris/urea, pH 8.0, and processed further to test <italic>ADAMTS13</italic> activity remaining.<xref ref-type="bibr" rid="B11">11</xref></p>
    <p>Human genomic DNA was isolated from whole blood. All exons of the <italic>ADAMTS13</italic> gene, including the intron-exon boundaries, were PCR-amplified with the primers used by Kokame, et al.<xref ref-type="bibr" rid="B6">6</xref> and Taq DNA polymerase. Products were sequenced in both directions by using a 3700 DNA Analyzer (Applied Biosystems, Foster City, CA, USA).</p>
    <p>Statistics were performed using SAS software (version 8.2) and Chi-square test. <italic>p</italic> value less than 0.05 was considered statistically significant.</p>
    <p>In 18 patients tested, 6 were D-HUS, and 12 D+HUS (<xref ref-type="table" rid="T1">Table 1</xref>). The median and range for plasma activity of <italic>ADAMTS13</italic> in 6 D-HUS and 12 D+HUS patients were 71.8% (22.8-94.1%) and 84.9% (37.9-119.9%), respectively, which were not statistically significantly different from the control group (86.4%, 34.2-112.3%) (<italic>p</italic>&gt;0.05). No inhibitory activity was detected in patients with <italic>ADAMTS13</italic> activity less than 44%.</p>
    <p>Five <italic>ADAMTS13</italic> gene mutations consisting of 2 novel mutations [1584+2T&gt;A, 3941C&gt;T (S1314L)] and 3 polymorphisms [Q448E, P475S, 2710C&gt;T (S903L)] were found in 3 HUS (2 D-HUS and one D+HUS) patients (<xref ref-type="fig" rid="F1">Fig. 1</xref>). All parents of these 3 HUS patients with <italic>ADAMTS13</italic> gene mutations are clinically unaffected. Two novel mutations, 1584 +2T&gt;A, and S1314L, were excluded as common polymorphisms by screening 100 Koreans.</p>
    <p>More than 60 mutations of the <italic>ADAMTS13</italic> gene have been found in patients with congenital TTP (The Human Gene Mutation Database at the Institute of Medical Genetics in Cadiff, <ext-link ext-link-type="uri" xlink:href="http://www.hgmd.ac.uk/ac/index.php">http://www.hgmd.ac.uk/ac/index.php</ext-link>). However, analysis of <italic>ADAMTS13</italic> gene mutations has generally been restricted to patients already carrying a clear diagnosis of congenital TTP, potentially presenting an ascertainment bias against the identification of mild mutations.<xref ref-type="bibr" rid="B12">12</xref></p>
    <p>While severe deficiency of <italic>ADAMTS13</italic> (&lt;10%) establishes a diagnosis of TTP unequivocally,<xref ref-type="bibr" rid="B13">13</xref> not all patients diagnosed with TTP have severe protease deficiency. In addition, <italic>ADAMTS13</italic> deficiency alone may not be sufficient to initiate an episode of clinical TTP.<xref ref-type="bibr" rid="B14">14</xref> Patients in clinical remission can still demonstrate ultralarge VWF multimers in the plasma and absence of <italic>ADAMTS13</italic> activity <italic>in vitro</italic>.<xref ref-type="bibr" rid="B3">3</xref> This heterogeneity suggests the presence of genetic modifying factors or environmental triggers other than <italic>ADAMTS13</italic> in TTP.<xref ref-type="bibr" rid="B1">1</xref></p>
    <p>Complement factor H mutation, known as a causative factor in D-HUS, and Shigatoxin, inducing the thrombotic state in D+HUS, were reported to be risk factors in TTP.<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B15">15</xref> In addition to the overlapping clinical features between TTP and HUS, these findings suggest possible role of <italic>ADAMTS13</italic> in HUS.</p>
    <p>Decreased <italic>ADAMTS13</italic> activity, usually mild to moderate (10 to 40% of normal plasma), has been reported in a wide variety of conditions, including liver cirrhosis, chronic uremia, idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, systemic lupus erythematosus, leukemia, pregnancy, the postoperative state, the neonatal period, and with advancing age<xref ref-type="bibr" rid="B16">16</xref> other than congenital TTP. As for HUS, <italic>ADAMTS13</italic> activity is normal or only slightly decreased in typical colitis-associated D+HUS, and severely deficient in a few D-HUS.<xref ref-type="bibr" rid="B17">17</xref></p>
    <p>In this study, <italic>ADAMTS13</italic> activities were not decreased in 18 HUS patients, which is consistent with previous reports.<xref ref-type="bibr" rid="B18">18</xref> Although the <italic>ADAMTS13</italic> activities were normal, we found mutations and polymorphisms of <italic>ADAMTS13</italic> gene in 2 D-HUS and one D+HUS patients. We cannot explain the genotype-phenotype dissociation in our 3 HUS patients with <italic>ADAMTS13</italic> gene mutations. Heterozygous mutation, distal location, or interaction with polymorphisms might be possible explanations.</p>
    <p>One D-HUS (patient 3) patient had heterozygous P475S polymorphism and moderate activity (53.9%) of <italic>ADAMTS13</italic> protease. P475S, a well known polymorphism located in the cysteine-rich domain,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B19">19</xref> was recombinantly analyzed and was found to be associated with a decline in the proteolytic activity of <italic>ADAMTS13</italic> (5-10% of wild type) despite normal secretion.<xref ref-type="bibr" rid="B20">20</xref> In Japan, the allele frequency of P475S is about 5%, suggesting that approximately 10% of population are heterozygotes and may possess significantly reduced <italic>ADAMTS13</italic> activity.<xref ref-type="bibr" rid="B19">19</xref></p>
    <p>The other D-HUS (patient 4) patient had a novel splicing mutation 1584+2T&gt;A in intron 13 (cysteine-rich domain). Also, this patient showed a homozygous S903L mutation in exon 21 (Tsp1-5 domain). Liu, et al.<xref ref-type="bibr" rid="B21">21</xref> reported a highly suspected congenital TTP patient with significantly reduced <italic>ADAMTS13</italic> activity and compound heterozygote mutation of S903L and R1095W in the <italic>ADAMTS13</italic> gene. Later, S903L was identified as a common polymorphism in Japanese with an allele frequency of 5.5% (7/64).<xref ref-type="bibr" rid="B22">22</xref> Polymorphisms influence the phenotypic expression of complex disease.<xref ref-type="bibr" rid="B17">17</xref> Dependent on the sequence context, the same polymorphisms might be either positive or negative modifiers of gene expression.<xref ref-type="bibr" rid="B20">20</xref> It is unclear whether polymorphism S903L is a positive modifier of <italic>ADAMTS13</italic> expression in the context of 1584+2T&gt;A splicing. The interaction between this splicing mutation and S903L polymorphism might explain normal <italic>ADAMTS13</italic> activity in this patient.</p>
    <p>One D+HUS (patient 7) patient had a novel heterozygous mutation of S1314L on exon 28 CUB2 domain and also heterozygous Q448E. It seems that the location S1314L mutation is too distal to have a detrimental effect on the <italic>ADAMTS13</italic> function. However, the cooperative activity between the middle carboxyl-terminal TSP1 repeats and the distal carboxyl-terminal CUB domains is crucial for recognition and cleavage of VWF under flow,<xref ref-type="bibr" rid="B23">23</xref> and more than 10% of <italic>ADAMTS13</italic> gene mutations associated with congenital TTP are located in the CUB domains.<xref ref-type="bibr" rid="B24">24</xref> As for Q448E, it is a positive modifier of <italic>ADAMTS13</italic> secretion in the context of P618A and A732V, and a negative modifier enhancing the detrimental effect of the missense mutation in the context of R1336W.<xref ref-type="bibr" rid="B20">20</xref> Expression tests would be necessary to elucidate the interaction between S1314L and Q448E.</p>
    <p>Limitation of this study is the lack of information on complement system except serum C3 levels. In D-HUS, 4 patients tested C3 levels had normal values. One D+HUS patient had low C3 level with unknown significance.</p>
    <p>To our best knowledge, this is the first report about <italic>ADAMTS13</italic> gene mutations and polymorphisms in childhood HUS in Korean population. Whether these mutations without reduced <italic>ADAMTS13</italic> activity are innocent bystanders or predisposing factors in HUS remains unanswered. In TTP, relapse is common among patients with <italic>ADAMTS13</italic> deficiency, but rarely occurs in patients without <italic>ADAMTS13</italic> deficiency.<xref ref-type="bibr" rid="B25">25</xref> In 6 D-HUS patients in this study, only the patient 3 and 4 underwent recurrent attack of HUS, suggesting the possibility that <italic>ADAMTS13</italic> gene mutations may act as a disease modifying or predisposing factor through an unexplained mechanism.</p>
    <p>In the future, expression tests are needed to identify the consequences of each <italic>ADAMTS13</italic> gene mutations and polymorphisms found in our HUS patients. Abnormalities in complement system and other genetic or environmental factors, involving TMA, should be investigated. In addition, VWF assay and mutation analysis would be a next assignment in our patients. Long-term follow-up of these HUS patients with <italic>ADAMTS13</italic> gene mutations might also provide an invaluable clue.</p>
  </body>
  <back>
    <ack>
      <title>ACKNOWLEDGEMENTS</title>
      <p>This study was supported by a grant (A080588) from the Korean Healthcare Technology R&amp;D Project, Ministry of Health, Welfare and Family Affairs, Republic of Korea. The authors thank Dr. Saewon Choi for his assistance in the preparation of this manuscript. We also thank all the physicians from the participating centers for providing clinical and biological data and plasma samples. The list of participating centers are as follows; Asan Medical Center, Cheongju St. Mary's Hospital, Chonnam National University Hospital, Eulji General Hospital, Hallym University Sacred Heart Hospital, Inha University Hospital, Inje University Pusan Paik Hospital, Inje University Sanggye Paik Hospital, Kangdong Sacred Heart Hospital, Pusan National University Hospital, Bundang Medical Center, CHA University Hospital, Seoul National University Hospital, Yonsei University Severance Hospital, and Yonsei University Wonju College of Medical Hospital.</p>
    </ack>
    <fn-group>
      <fn fn-type="conflict">
        <p>The authors have no financial conflicts of interest.</p>
      </fn>
    </fn-group>
    <ref-list>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>The molecular biology of thrombotic microangiopathy</article-title>
          <source>Kidney Int</source>
          <year>2006</year>
          <volume>70</volume>
          <fpage>16</fpage>
          <lpage>23</lpage>
          <pub-id pub-id-type="pmid">16760911</pub-id>
        </element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Desch</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Motto</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Is there a shared pathophysiology for thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome?</article-title>
          <source>J Am Soc Nephrol</source>
          <year>2007</year>
          <volume>18</volume>
          <fpage>2457</fpage>
          <lpage>2460</lpage>
          <pub-id pub-id-type="pmid">17687074</pub-id>
        </element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furlan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Galbusera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Remuzzi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kyrle</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Brenner</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome</article-title>
          <source>N Engl J Med</source>
          <year>1998</year>
          <volume>339</volume>
          <fpage>1578</fpage>
          <lpage>1584</lpage>
          <pub-id pub-id-type="pmid">9828245</pub-id>
        </element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Lian</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title>Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura</article-title>
          <source>N Engl J Med</source>
          <year>1998</year>
          <volume>339</volume>
          <fpage>1585</fpage>
          <lpage>1594</lpage>
          <pub-id pub-id-type="pmid">9828246</pub-id>
        </element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Nichols</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Lian</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Foroud</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>McClintick</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>McGee</surname>
              <given-names>BM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura</article-title>
          <source>Nature</source>
          <year>2001</year>
          <volume>413</volume>
          <fpage>488</fpage>
          <lpage>494</lpage>
          <pub-id pub-id-type="pmid">11586351</pub-id>
        </element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kokame</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Soejima</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Yagi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ishizashi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Funato</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity</article-title>
          <source>Proc Natl Acad Sci U S A</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>11902</fpage>
          <lpage>11907</lpage>
          <pub-id pub-id-type="pmid">12181489</pub-id>
        </element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tarr</surname>
              <given-names>PI</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Chandler</surname>
              <given-names>WL</given-names>
            </name>
          </person-group>
          <article-title>Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome</article-title>
          <source>Lancet</source>
          <year>2005</year>
          <volume>365</volume>
          <fpage>1073</fpage>
          <lpage>1086</lpage>
          <pub-id pub-id-type="pmid">15781103</pub-id>
        </element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loirat</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Noris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Fremeaux-Bacchi</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Complement and the atypical hemolytic uremic syndrome in children</article-title>
          <source>Pediatr Nephrol</source>
          <year>2008</year>
          <volume>23</volume>
          <fpage>1957</fpage>
          <lpage>1972</lpage>
          <pub-id pub-id-type="pmid">18594873</pub-id>
        </element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caprioli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Noris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brioschi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pianetti</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Castelletti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bettinaglio</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>108</volume>
          <fpage>1267</fpage>
          <lpage>1279</lpage>
          <pub-id pub-id-type="pmid">16621965</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furlan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Robles</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Morselli</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Sandoz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>LÃ¤mmle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura</article-title>
          <source>Thromb Haemost</source>
          <year>1999</year>
          <volume>81</volume>
          <fpage>8</fpage>
          <lpage>13</lpage>
          <pub-id pub-id-type="pmid">10348715</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schneppenheim</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Budde</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Oyen</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Angerhaus</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Aumann</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Drewke</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>101</volume>
          <fpage>1845</fpage>
          <lpage>1850</lpage>
          <pub-id pub-id-type="pmid">12393505</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Levy</surname>
              <given-names>GG</given-names>
            </name>
            <name>
              <surname>Motto</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Ginsburg</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS13 turns 3</article-title>
          <source>Blood</source>
          <year>2005</year>
          <volume>106</volume>
          <fpage>11</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="pmid">15774620</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mannucci</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Peyvandi</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>TTP and ADAMTS13: When Is Testing Appropriate?</article-title>
          <source>Hematology Am Soc Hematol Educ Program</source>
          <year>2007</year>
          <fpage>121</fpage>
          <lpage>126</lpage>
          <pub-id pub-id-type="pmid">18024619</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Vesely</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>ADAMTS13 and TTP: the clot thickens</article-title>
          <source>Blood</source>
          <year>2004</year>
          <volume>103</volume>
          <fpage>3997</fpage>
          <lpage>3998</lpage>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Motto</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Chauhan</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Homeister</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lamb</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Desch</surname>
              <given-names>KC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice</article-title>
          <source>J Clin Invest</source>
          <year>2005</year>
          <volume>115</volume>
          <fpage>2752</fpage>
          <lpage>2761</lpage>
          <pub-id pub-id-type="pmid">16200209</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mannucci</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Canciani</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Forza</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lussana</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lattuada</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Changes in health and disease of the metalloprotease that cleaves von Willebrand factor</article-title>
          <source>Blood</source>
          <year>2001</year>
          <volume>98</volume>
          <fpage>2730</fpage>
          <lpage>2735</lpage>
          <pub-id pub-id-type="pmid">11675345</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loof</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>van Vliet</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Kappers-Klunne</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura</article-title>
          <source>Br J Haematol</source>
          <year>2001</year>
          <volume>112</volume>
          <fpage>1087</fpage>
          <lpage>1088</lpage>
          <pub-id pub-id-type="pmid">11324640</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vesely</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>LÃ¤mmle</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Studt</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Alberio</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>El-Harake</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients</article-title>
          <source>Blood</source>
          <year>2003</year>
          <volume>102</volume>
          <fpage>60</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="pmid">12637323</pub-id>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kokame</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Genetic defects leading to hereditary thrombotic thrombocytopenic purpura</article-title>
          <source>Semin Hematol</source>
          <year>2004</year>
          <volume>41</volume>
          <fpage>34</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">14727257</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Plaimauer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fuhrmann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mohr</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Wernhart</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bruno</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ferrari</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation</article-title>
          <source>Blood</source>
          <year>2006</year>
          <volume>107</volume>
          <fpage>118</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="pmid">16160007</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>NZ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>YG</given-names>
            </name>
            <name>
              <surname>Ruan</surname>
              <given-names>CG</given-names>
            </name>
          </person-group>
          <article-title>[Identification of two novel mutations in ADAMTS13 gene in a patient with hereditary thrombotic thrombocytopenic purpura]</article-title>
          <source>Zhonghua Xue Ye Xue Za Zhi</source>
          <year>2005</year>
          <volume>26</volume>
          <fpage>521</fpage>
          <lpage>524</lpage>
          <pub-id pub-id-type="pmid">16468327</pub-id>
        </element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shibagaki</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kokame</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Ohba</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Miyata</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fujimura</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Novel compound heterozygote mutations (H234Q/R1206X) of the ADAMTS13 gene in an adult patient with Upshaw-Schulman syndrome showing predominant episodes of repeated acute renal failure</article-title>
          <source>Nephrol Dial Transplant</source>
          <year>2006</year>
          <volume>21</volume>
          <fpage>1289</fpage>
          <lpage>1292</lpage>
          <pub-id pub-id-type="pmid">16449289</pub-id>
        </element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Rux</surname>
              <given-names>AH</given-names>
            </name>
            <name>
              <surname>Sachais</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>XL</given-names>
            </name>
          </person-group>
          <article-title>The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow</article-title>
          <source>Blood</source>
          <year>2007</year>
          <volume>110</volume>
          <fpage>1887</fpage>
          <lpage>1894</lpage>
          <pub-id pub-id-type="pmid">17540842</pub-id>
        </element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Structural and functional correlation of ADAMTS13</article-title>
          <source>Curr Opin Hematol</source>
          <year>2007</year>
          <volume>14</volume>
          <fpage>270</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="pmid">17414218</pub-id>
        </element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>George</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Terrell</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Swisher</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Vesely</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry</article-title>
          <source>J Clin Apher</source>
          <year>2008</year>
          <volume>23</volume>
          <fpage>129</fpage>
          <lpage>137</lpage>
          <pub-id pub-id-type="pmid">18618590</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Fig. 1</label>
      <caption>
        <p><italic>ADAMTS13</italic> gene structure and mutation sites in 3 HUS patients. <sup>*</sup>Three polymorphisms are indicated by italics. HUS, hemolytic uremic syndrome; S, signal peptide; P, propeptide; MP, metalloprotease domain; D, disintegrin-like domain; T, TSP1 motif; Cys, cysteine-rich domain; Sp, spacer domain; C, CUB domain.</p>
      </caption>
      <graphic xlink:href="ymj-52-530-g001"/>
    </fig>
    <table-wrap id="T1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Patients Characteristics</p>
      </caption>
      <graphic xlink:href="ymj-52-530-i001"/>
      <table-wrap-foot>
        <fn>
          <p>C3 normal range 77-195 mg/dL.</p>
          <p>FHx, family history; ND, not done; MicroHU, microscopic hematuria; KidT, kidney transplantation; HTN, hypertension; MicroP/HU, microscopic proteinuria and microscopic hematuria.</p>
          <p><sup>*</sup>Patients with <italic>ADAMTS13</italic> gene mutations and/or polymorphisms.</p>
          <p><sup>â </sup>Homozygote.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>